James William Rogers Sells 10,853 Shares of Tempus AI (NASDAQ:TEM) Stock

Tempus AI, Inc. (NASDAQ:TEM) CFO James William Rogers sold 10,853 shares of Tempus AI stock in a transaction that occurred on Tuesday, May 19th. The stock was sold at an average price of $44.07, for a total transaction of $478,291.71. Following the completion of the sale, the chief financial officer directly owned 126,395 shares of the company’s stock, valued at $5,570,227.65. The trade was a 7.91% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Tempus AI Trading Up 1.3%

TEM stock traded up $0.61 during midday trading on Thursday, hitting $46.49. The stock had a trading volume of 3,802,434 shares, compared to its average volume of 5,629,236. The firm has a market cap of $8.35 billion, a PE ratio of -27.03 and a beta of 3.99. The company has a debt-to-equity ratio of 2.96, a current ratio of 3.31 and a quick ratio of 3.15. Tempus AI, Inc. has a 12-month low of $41.73 and a 12-month high of $104.32. The company’s 50-day moving average price is $49.11 and its 200 day moving average price is $59.69.

Tempus AI (NASDAQ:TEM) last released its earnings results on Tuesday, May 5th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.21) by $0.08. Tempus AI had a negative net margin of 22.20% and a negative return on equity of 53.83%. The firm had revenue of $348.12 million during the quarter, compared to analysts’ expectations of $345.44 million. During the same period in the previous year, the company earned ($0.24) EPS. Tempus AI’s revenue for the quarter was up 36.1% on a year-over-year basis. On average, equities research analysts predict that Tempus AI, Inc. will post -1.35 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in TEM. JPL Wealth Management LLC purchased a new stake in shares of Tempus AI during the 3rd quarter worth about $26,000. Los Angeles Capital Management LLC purchased a new stake in shares of Tempus AI during the 4th quarter worth about $27,000. Harvest Fund Management Co. Ltd purchased a new stake in shares of Tempus AI during the 3rd quarter worth about $38,000. Whittier Trust Co. grew its holdings in shares of Tempus AI by 190.0% during the 1st quarter. Whittier Trust Co. now owns 870 shares of the company’s stock worth $41,000 after purchasing an additional 570 shares during the period. Finally, Lodestone Wealth Management LLC purchased a new stake in shares of Tempus AI during the 4th quarter worth about $42,000. 24.22% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Tempus AI in a research report on Thursday, January 22nd. Robert W. Baird initiated coverage on shares of Tempus AI in a report on Tuesday, February 17th. They issued an “outperform” rating and a $59.00 target price for the company. TD Cowen boosted their target price on shares of Tempus AI from $65.00 to $68.00 and gave the company a “buy” rating in a report on Wednesday, May 6th. Needham & Company LLC restated a “buy” rating and issued a $75.00 target price on shares of Tempus AI in a report on Wednesday, March 11th. Finally, Mizuho initiated coverage on shares of Tempus AI in a report on Thursday, February 19th. They issued an “outperform” rating and a $100.00 target price for the company. Nine analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $68.64.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.